


**In the claims:**

Please amend claims 1, 7-10 and 18 to read as follows:

1. (Amended) A composition of matter comprising the structure



wherein:

F<sup>1</sup> is a vehicle;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>, and -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>-(L<sup>4</sup>)<sub>f</sub>-P<sup>4</sup>

P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> are each independently selected from SEQ ID NOS: 45 and 46;

L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, and L<sup>4</sup> are each independently linkers that are not naturally occurring amino acid sequences found in SEQ ID NO:42; and

a and b are each independently 0 or 1, provided that at least one of a and b is 1;

c, d, e, and f are each independently 0 or 1, provided that if P<sup>1</sup> is SEQ ID NO: 45 and P<sup>2</sup> is SEQ ID NO: 46, then d is 1;


wherein said composition of matter does not comprise SEQ ID NO: 43, and is capable of binding AGP-3.

7. (Amended) The composition of matter of Claim 1, wherein F<sup>1</sup> is a water-soluble polymer or a carbohydrate.

8. (Amended) The composition of matter of Claim 7, wherein the polymer is polyethylene glycol.

9. (Amended) The composition of matter of Claim 7, wherein the carbohydrate is dextran.

10. (Amended) A polypeptide comprising the structure



wherein:

F<sup>1</sup> is a vehicle;

X<sup>1</sup> and X<sup>2</sup> are each independently selected from -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>, -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>, and -(L<sup>1</sup>)<sub>c</sub>-P<sup>1</sup>-(L<sup>2</sup>)<sub>d</sub>-P<sup>2</sup>-(L<sup>3</sup>)<sub>e</sub>-P<sup>3</sup>-(L<sup>4</sup>)<sub>f</sub>-P<sup>4</sup>

P<sup>1</sup>, P<sup>2</sup>, P<sup>3</sup>, and P<sup>4</sup> are each independently selected from SEQ ID NOS: 45 and 46;

L<sup>1</sup>, L<sup>2</sup>, L<sup>3</sup>, and L<sup>4</sup> are each independently linkers that are not naturally occurring amino acid sequences found in SEQ ID NO:42; and

a and b are each independently 0 or 1, provided that at least one of a and b is 1;

c, d, e, and f are each independently 0 or 1, provided that if P<sup>1</sup> is SEQ ID NO: 45 and P<sup>2</sup> is SEQ ID NO: 46, then d is 1;

wherein said polypeptide does not comprise SEQ ID NO: 43, and is capable of binding AGP-3.

---

18. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of a protein of Claim 10 in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.

---